Alkaloid Derivative (Z)-3β-Ethylamino-Pregn-17(20)-en Inhibits Triple-Negative Breast Cancer Metastasis and Angiogenesis by Targeting HSP90α |
| |
| Authors: | Xin-Yao Liu Yu-Miao Wang Xiang-Yu Zhang Mei-Qi Jia Hong-Quan Duan Nan Qin Ying Chen Yang Yu Xiao-Chuan Duan |
| |
| Affiliation: | 1.School of Pharmacy, Tianjin Medical University, Tianjin 300070, China;2.Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China;3.Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Medical University, Tianjin 300070, China;4.School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin 300070, China |
| |
| Abstract: | ![]()
Metastasis is an important cause of cancer-related death. Previous studies in our laboratory found that pregnane alkaloids from Pachysandra terminalis had antimetastatic activity against breast cancer cells. In the current study, we demonstrated that treatment with one of the alkaloid derivatives, (Z)-3β-ethylamino-pregn-17(20)-en (1), led to the downregulation of the HIF-1α/VEGF/VEGFR2 pathway, suppressed the phosphorylation of downstream molecules Akt, mTOR, FAK, and inhibited breast cancer metastasis and angiogenesis both in vitro and in vivo. Furthermore, the antimetastasis and antiangiogenesis effects of 1 treatment (40 mg/kg) were more effective than that of Sorafenib (50 mg/kg). Surface plasmon resonance (SPR) analysis was performed and the result suggested that HSP90α was a direct target of 1. Taken together, our results suggested that compound 1 might represent a candidate antitumor agent for metastatic breast cancer. |
| |
| Keywords: | compound 1, triple-negative breast cancer, antimetastasis, antiangiogenesis, HSP90α , HIF-1α /VEGF/VEGFR2 |
|
|
